Review of clinical trials in intraoperative molecular imaging during cancer surgery

John Y.K. Lee, Steve S. Cho, Walter Stummer, Janos L. Tanyi, Alexander L. Vahrmeijer, Eben Rosenthal, Barbara Smith, Eric Henderson, David W. Roberts, Amy Lee, Constantinos G. Hadjipanayis, Jeffrey N. Bruce, Jason G. Newman, Sunil Singhal

Research output: Contribution to journalArticle

Abstract

Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of biomedical optics
Volume24
Issue number12
DOIs
StatePublished - Dec 1 2019

Fingerprint

Molecular imaging
surgeons
surgery
Surgery
Contrast Media
neoplasms
cancer
Tumors
Fluorescence
Imaging techniques
horizon
emerging
drugs
tumors
Pharmaceutical Preparations
fluorescence

Keywords

  • fluorescence-guided surgery
  • intraoperative visualization
  • molecular imaging
  • tumor surgery

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering

Cite this

Lee, J. Y. K., Cho, S. S., Stummer, W., Tanyi, J. L., Vahrmeijer, A. L., Rosenthal, E., ... Singhal, S. (2019). Review of clinical trials in intraoperative molecular imaging during cancer surgery. Journal of biomedical optics, 24(12), 1-8. https://doi.org/10.1117/1.JBO.24.12.120901

Review of clinical trials in intraoperative molecular imaging during cancer surgery. / Lee, John Y.K.; Cho, Steve S.; Stummer, Walter; Tanyi, Janos L.; Vahrmeijer, Alexander L.; Rosenthal, Eben; Smith, Barbara; Henderson, Eric; Roberts, David W.; Lee, Amy; Hadjipanayis, Constantinos G.; Bruce, Jeffrey N.; Newman, Jason G.; Singhal, Sunil.

In: Journal of biomedical optics, Vol. 24, No. 12, 01.12.2019, p. 1-8.

Research output: Contribution to journalArticle

Lee, JYK, Cho, SS, Stummer, W, Tanyi, JL, Vahrmeijer, AL, Rosenthal, E, Smith, B, Henderson, E, Roberts, DW, Lee, A, Hadjipanayis, CG, Bruce, JN, Newman, JG & Singhal, S 2019, 'Review of clinical trials in intraoperative molecular imaging during cancer surgery', Journal of biomedical optics, vol. 24, no. 12, pp. 1-8. https://doi.org/10.1117/1.JBO.24.12.120901
Lee, John Y.K. ; Cho, Steve S. ; Stummer, Walter ; Tanyi, Janos L. ; Vahrmeijer, Alexander L. ; Rosenthal, Eben ; Smith, Barbara ; Henderson, Eric ; Roberts, David W. ; Lee, Amy ; Hadjipanayis, Constantinos G. ; Bruce, Jeffrey N. ; Newman, Jason G. ; Singhal, Sunil. / Review of clinical trials in intraoperative molecular imaging during cancer surgery. In: Journal of biomedical optics. 2019 ; Vol. 24, No. 12. pp. 1-8.
@article{1dae16f3e19b4b2682074e31d977d55d,
title = "Review of clinical trials in intraoperative molecular imaging during cancer surgery",
abstract = "Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.",
keywords = "fluorescence-guided surgery, intraoperative visualization, molecular imaging, tumor surgery",
author = "Lee, {John Y.K.} and Cho, {Steve S.} and Walter Stummer and Tanyi, {Janos L.} and Vahrmeijer, {Alexander L.} and Eben Rosenthal and Barbara Smith and Eric Henderson and Roberts, {David W.} and Amy Lee and Hadjipanayis, {Constantinos G.} and Bruce, {Jeffrey N.} and Newman, {Jason G.} and Sunil Singhal",
year = "2019",
month = "12",
day = "1",
doi = "10.1117/1.JBO.24.12.120901",
language = "English (US)",
volume = "24",
pages = "1--8",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "12",

}

TY - JOUR

T1 - Review of clinical trials in intraoperative molecular imaging during cancer surgery

AU - Lee, John Y.K.

AU - Cho, Steve S.

AU - Stummer, Walter

AU - Tanyi, Janos L.

AU - Vahrmeijer, Alexander L.

AU - Rosenthal, Eben

AU - Smith, Barbara

AU - Henderson, Eric

AU - Roberts, David W.

AU - Lee, Amy

AU - Hadjipanayis, Constantinos G.

AU - Bruce, Jeffrey N.

AU - Newman, Jason G.

AU - Singhal, Sunil

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.

AB - Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied.

KW - fluorescence-guided surgery

KW - intraoperative visualization

KW - molecular imaging

KW - tumor surgery

UR - http://www.scopus.com/inward/record.url?scp=85076265403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076265403&partnerID=8YFLogxK

U2 - 10.1117/1.JBO.24.12.120901

DO - 10.1117/1.JBO.24.12.120901

M3 - Article

C2 - 31808327

AN - SCOPUS:85076265403

VL - 24

SP - 1

EP - 8

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 12

ER -